142 related articles for article (PubMed ID: 17318776)
1. The use of i. v. bisphosphonate in pregnancy-associated osteoporosis--case study.
Hellmeyer L; Kühnert M; Ziller V; Schmidt S; Hadji P
Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):139-42. PubMed ID: 17318776
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of 1-34 parathyroid hormone (PTH) after failure of bisphosphonate therapy in a complex case of pregnancy associated osteoporosis and multiple fractures.
Winarno AS; Kyvernitakis I; Hadji P
Z Geburtshilfe Neonatol; 2014 Aug; 218(4):171-3. PubMed ID: 25127351
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features of pregnancy and lactation-associated osteoporosis: analysis of 4 cases].
He XD; Xia WB; Xing XP; Li M; Jiang Y; Wang O; Xu LL; Xu JP
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(14):983-5. PubMed ID: 19671313
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.
Li LJ; Zhang J; Gao P; Lv F; Song YW; Chang XY; Zhao DC; Wang O; Jiang Y; Xing XP; Xia WB; Li M
Clin Rheumatol; 2018 Nov; 37(11):3141-3150. PubMed ID: 29946989
[TBL] [Abstract][Full Text] [Related]
5. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
Ringe JD; Dorst A; Faber H
Osteoporos Int; 2005 Dec; 16(12):2063-8. PubMed ID: 16228105
[TBL] [Abstract][Full Text] [Related]
6. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
7. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
9. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
Sebba AI
Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
[TBL] [Abstract][Full Text] [Related]
10. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
[TBL] [Abstract][Full Text] [Related]
11. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in pregnancy and lactation-associated osteoporosis.
O'Sullivan SM; Grey AB; Singh R; Reid IR
Osteoporos Int; 2006; 17(7):1008-12. PubMed ID: 16758139
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy associated osteoporosis--a case report.
Dytfeld J; Horst-Sikorska W
Ginekol Pol; 2012 May; 83(5):377-9. PubMed ID: 22708337
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
Hashimoto J
Clin Calcium; 2007 Jan; 17(1):11-7. PubMed ID: 17211088
[TBL] [Abstract][Full Text] [Related]
16. Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.
Mastaglia SR; Watman NP; Oliveri B
Osteoporos Int; 2010 Nov; 21(11):1959-62. PubMed ID: 20535608
[TBL] [Abstract][Full Text] [Related]
17. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
18. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
19. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
